Ligand Pharmaceuticals (LGND) Cost of Revenue (2011 - 2026)

Ligand Pharmaceuticals has reported Cost of Revenue for 16 years, with the latest figure at $3.3 million in Q1 2026.

• Quarterly Cost of Revenue fell 32.5% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (down 0.52% YoY) and the FY2025 annual result came in at $14.5 million, up 31.38% from the prior year.
• Cost of Revenue advanced to $3.3 million in Q1 2026 per LGND's latest filing, from $3.0 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $21.6 million in Q4 2022 and troughed at $1.6 million in Q4 2023.
• A 5-year average of $5.4 million and a median of $3.3 million in 2026 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 80.36% in 2022, then sank 92.41% in 2023.
• Over 5 years, Cost of Revenue stood at $21.6 million in 2022, then tumbled by 92.41% to $1.6 million in 2023, then surged by 72.88% to $2.8 million in 2024, then grew by 5.46% to $3.0 million in 2025, then climbed by 9.39% to $3.3 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $3.3 million, $3.0 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.